While Conbercept's additional structural domain might suggest greater efficacy, this doesn't necessarily translate to clinical significance.As AMD is influenced by various factors, patients' responses to anti-VEGF treatments can vary, with some experiencing reduced effectiveness over time.Notably, despite these treatments, AMD-related blindness incidences continue to increase annually28. This evidence concerns the gene VEGFA and blindness (disorder).